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Abstract
Using single-nucleotide polymorphisms (SNPs), we sought to predict classical class I and class II
human leukocyte antigen (HLA) alleles, and test for their associations with rheumatoid arthritis
(RA) in the North American Rheumatoid Arthritis Consortium sample of cases and controls,
genotyped on the Illumina HumanHap550 BeadChip. We use publicly available databases of SNP
data and HLA data to find SNPs or SNP-haplotypes to be used as surrogates for each HLA allele. To
reduce the confounding effects of linkage disequilibrium with the HLA-DRB1 locus, we tested for
the association conditional on the presence or absence of a shared epitope allele on the same
haplotype as the target HLA allele. Using SNP surrogates, we find that components of the DQ8
serotype (DQA1*0301:DQB1*0302) are associated with RA, irrespective of the presence or
absence of a shared epitope allele on their respective haplotypes. Knowledge of the haplotype
structure in the HLA region is still necessary for better interpretation of the results.
Background
The human leukocyte antigen (HLA)-DRB1 locus has long
been recognized as a strong genetic risk factor for
rheumatoid arthritis (RA), yet it explains less than half of
the estimated genetic susceptibility to the disease [1]. Large-
scale studies that interrogate the whole genome have
uncovered, at strict significance thresholds, genetic risk
variants outside the major histocompatibility complex
(MHC) [2-4], while also replicating known associations
from candidate gene studies [5]. The difficulty in evaluating
the role of other candidate loci from the MHC region in the
etiology of the disease resides in the strong linkage
disequilibrium (LD) and the extended haplotype structure
that exists in this highly polymorphic portion of the
genome. We seek to evaluate the risk of other HLA loci, by
using SNP data and publicly available HLA data, in order
to predict and evaluate the effect of classical class I and
class II HLA alleles in the North American Rheumatoid
Arthritis Consortium (NARAC) case-control dataset [3], as
distributed for use at the Genetic Analysis Workshop 16.
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The NARAC sample consists of 868 cases of RA and 1194
controls, all genotyped on the Illumina HumanHap550
BeadChip, or equivalent. The sample is fully described
by Plenge et al. [3]. The sample also includes HLA-DRB1
alleles, typed at various resolutions. The susceptibility
alleles at DRB1 tend to share the RAA motif in position
72-74 of the amino acid sequence, an observation that
led to the hypothesis of a functional unit, called the
shared epitope (SE) [6]. Amino acids found in positions
70-71 provide further refinement of the classification of
DRB1 risk alleles [7].
To predict classical HLA alleles from SNP data, we followed
the methods described by de Bakker et al. [8]. They typed
six class I and class II HLA genes (A, B, C, DQA1, DQB1,
and DRB1) in a set of samples that includes the CEU
samples from the HapMap (Utah residents with ancestry
from northern and western Europe). Most of the HLA
alleles they report are at a resolution of four digits. We used
this publicly available dataset, combined with SNP
genotype data from the HapMap that are in the broad
MHC region (chr6: 25, 990, 507...33, 893, 423 [hg18]),
and that overlap with the set of SNPs on the Illumina
HumanHap550 BeadChip. Using the CEU HapMap data
combined with the CEU HLA data from de Bakker et al.
[8], we searched for tags for each of the HLA alleles,
considering up to three-SNP haplotypes as potential
predictors. The best predictor was chosen based on the
largest observed r
2 measure of LD (where, for each target
HLA allele, we merged all other alleles at that locus into a
single one, to mimic a biallelic locus; the same for multiple
SNP haplotypes). To be considered a potential predictor
of HLA alleles, a SNP had to be in Hardy-Weinberg
equilibrium (p > 0.00001) in the set of controls from the
NARAC dataset, and had to have a call rate above 95% over
all samples. We used the program Tagger [9] as imple-
mented in computer program Haploview [10] to predict
the HLA alleles from the HapMap SNP data.
We tested for the association between RA and the class I
and class II (non DRB1) HLA alleles, using the SNP
predictors as surrogates. Because the DRB1 locus is a
strong risk factor for RA, we reduced the confounding
effects of LD by performing the analysis conditional on
whether each of the two alleles found at the DRB1 locus
are members of the SE class of alleles, considering this
conditioning argument as if it was a biallelic locus. We
used the computer program UNPHASED [11] to perform
the conditional tests of association. For each target HLA
allele, we report two conditional odds ratios (ORs):
these are ORs for the target HLA allele given the presence
(SE+) or absence (SE-) of an SE allele on its haplotype.
Among the four-digit alleles that are classified as SE+
(according to the classification of du Montcel et al. [7]),
those that were actually observed in the NARAC samples
only include DRB1*0101, *0102, *0401, *0404, *0405,
*0408, and *1001.
The NARAC sample is affected by population substruc-
ture, with chi-square statistics reported to be inflated on
average by a factor ~ 1.4 [3]. To account for the hidden
ancestry of all cases and controls, we computed the
spectral decomposition of a covariance matrix between
all DNA samples and used its eigenvectors as surrogates
for ancestry [12]. The covariance matrix was calculated
using a set of ~ 120,000 autosomal SNPs that are at
most modestly correlated (pairwise r
2 < 0.30), a set that
excludes SNPs on the short arm of chromosome 6 and
on the short arm of chromosome 8 (for reasons
explained by Plenge et al. [3]). As in Plenge et al. [3],
we found seven outliers by inspecting the eigenvectors
associated with the top 10 eigenvalues: their respective
entries in at least one eigenvector differed from the mean
by more than six standard deviations. We removed these
seven outliers from any downstream analyses, and
recomputed the eigenvectors. As in Plenge et al. [3],
the top three vectors that are statistically significant
predictors of case-control status were used as surrogates
for the hidden ancestry of all samples, and were used to
correct for the effects of population stratification. By
using them as covariates in a logistic regression frame-
work, the inflation factor of all association results,
excluding results on the short arm of chromosome 6,
was calculated to be 1.035. This value is similar to what
has been calculated by Plenge et al. [3]. We used these
three vectors as potential confounders in UNPHASED.
Results
We only report the results of the conditional tests of
association for those HLA alleles that can be predicted
from the set of SNPs described in Methods at an r
2 >0 . 8 0
(47 out of the 70 non-DRB1 HLA alleles, or 67%), and
that moreover show conditional association at the level
p<0.001.Table1shows,foreachHLAallele,itsfrequency
as estimated from the data from de Bakker et al. [8], the
SNP or the combination of SNPs that can be used to
predict the HLA allele, along with the predictor allele or
haplotype, and the strength of the prediction in terms of
the r
2 measure of LD. It also shows the results of the
conditionaltestsofassociation,includingtheconditional
ORs and their confidence intervals.
We find that two class II alleles, DQA1*0301 and
DQB1*0302, and one class I allele, B*0801, show
significant association with RA irrespective of the
presence or absence, on their respective haplotypes, of
an SE allele at the DRB1 locus. For DQA1*0301, both
conditional ORs are estimated to take the same value,
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-12). For DQB1*0302, the risk is higher
when not combined with an SE allele (2.23 versus 1.38,
p = 0.0002). The alpha and beta chains DQA1*0301/
DQB1*0302 together form the DQ8 serotype [13]. That
they are co-associated is thus not surprising. DQ8 has
been shown to be associated with RA in humans [14],
but this association was thought to be due to LD with
DRB1*0401 and *0405 (two SE alleles). Our results are
indicative of DQ8 being a risk factor independent of the
risk alleles, or non-risk alleles, found at DRB1 (but see
Discussion). For the class I allele B*0801, the OR is 1.54
when its haplotype does not contain an SE allele, while it
is 3.03 otherwise (p = 0.00018). B*0801 is found on the
ancestral 8.1 haplotype, which has been shown to carry
risk for RA as well as DRB1*03, a non-SE allele [15]. All
other HLA alleles from Table 1 show significant decrease
in risk only when combined with an SE allele (see
Discussion).
Discussion
Conditioning on the presence or absence of SE alleles on
t h es a m eh a p l o t y p ea st h et e s ta l l e l ea to t h e rH L Al o c i
helps reduce the confounding effects of LD with
the DRB1 locus, but since different DRB1 alleles, or
combinations thereof, show a wide spectrum of risks,
this conditioning argument is not sufficient on its own
to fully account for DRB1. Knowledge of the haplotype
structure in the MHC region is still necessary for a better
interpretation of the results. For instance, the apparent
protection that seems to be conferred by DQB1*0501 or
DQA1*0101 (Table 1) is a mere reflection of the fact that
these two alleles are in LD with DR1/DR10 [16], which
although they are risk factors for RA, they are not the
most prominent ones [14]. Moreover, the classical HLA
alleles that we report in the present study are only
p r e d i c t e df r o mt h eS N Pd a t aa th a n d ,s o m e t i m e s
imperfectly, and based on only a small sample (in our
case, the HapMap CEU samples). Thus, it is still unclear
if the associations seen between DQA1*0301/
DQB1*0302 (the DQ8 serotype) and RA truly reflect
r i s k st h a ta r ei n d e p e n d e n to fD R B 1 ,o rr a t h e ra r ea r t i f a c t s
of the measurement errors inherent to any tagging
procedure. In terms of the power to detect disease-
associated HLA alleles, a penalty is incurred when using
SNPs or SNP-haplotypes as surrogates for them, because
the sample size required to achieve a given power is
inversely proportional to the r
2 measure of LD between
them [17]. Yet, as a proof-of-concept and justification for
the more expensive typing of HLA alleles at high
resolution, using SNP data and publicly available
databases of HLA data to predict classical class I and
class II alleles is an efficient method for preliminary
evaluation of the role of HLA genes in the etiology of
autoimmune, infectious or other relevant diseases.
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d OR CI-low CI-high OR CI-low CI-high
DQA*0301 0.27 rs660895 (G) 0.96 2.13 × 10
-12 2.11 1.38 3.24 2.11 1.65 2.71
DQB*0501 0.11 rs17533090, rs9275406, rs9275439 (AAG) 1.00 4.30 × 10
-11 0.33 0.04 2.61 0.43 0.33 0.55
DQA*0101 0.13 rs9268832, rs2395185, rs7774434 (GCG) 0.80 5.12 × 10
-08 0.58 0.20 1.68 0.48 0.37 0.62
B*0801 0.16 rs3134792 (C) 1.00 1.86 × 10
-4 1.54 1.03 2.30 3.03 1.27 7.23
DQB*0302 0.19 rs9275312 (G) 0.94 1.96 × 10
-4 2.23 1.28 3.89 1.38 1.07 1.79
C*0401 0.08 rs9264904 (A) 1.00 1.99 × 10
-4 0.85 0.56 1.30 0.59 0.44 0.79
aFrequency estimated from the data of de Bakker et al. [8].
bAlleles or haplotypes used as surrogate for the HLA alleles, with corresponding SNPs.
cr
2 measure of linkage disequilibrium between the HLA allele and the surrogate.
dp-value for the two degrees of freedom conditional test of association.
eOdds ratio and 95% confidence interval for HLA alleles on non-SE allele bearing haplotypes.
fOdds ratio and 95% confidence interval for HLA alleles on SE allele bearing haplotypes.
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